One more stock in the biotechnology and drugs complex whose insiders are buying up shares of Is Chelsea Therapeutics (CHTP), a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. This stock is off to a weak start in 2012, with shares down by around 10%.
Chelsea Therapeutics has a market cap of $287 million and an enterprise value of $223 million. This stock trades at a high valuation, with a price-to-book of 6.19. Its estimated growth rate for this year is -5.5%, and for next year it's pegged at 24%. This is a cash-rich company, since the total cash position on its balance sheet is $57.61 million and its total debt is zero.A beneficial owner just bought 40,000 shares, or about $192,000 worth of stock, at $4.80 per share. Back in November, the chief medical officer also bought 45,141 shares, or around $200,000 worth of stock, at $4.46 per share. From a technical standpoint, CHTP is currently trading below both its 50-day and 200-day moving averages, which is bearish. This stock hit a recent bottom at $3.25 in October, and since then it has trended higher towards its current price of $4.60. This stock is now approaching a bullish trade setup if it can manage to clear its 200-day moving average. If you're bullish on CHTP, I would look to be a buyer on a sustained high-volume move or close back above its 200-day moving average of $4.65 a share. Look for volume that's tracking in close to or above its three-month average action of 469,229 shares. If we get that action, I would then look to add to any long positions once CHTP takes out its 50-day moving average of $4.99 with volume. To see more stocks with notable insider buying like Senesco Technologies (CNT), MRV Communications (MRVC) and Geoeye (GEOY), check out the Stocks With Big Insider Buying portfolio on Stockpickr. -- Written by Roberto Pedone in Winderemere, Fla.
Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV